ST13, Hsp70 interacting protein pseudogene 16Genealiases: []
Q-omics provides the consensus-scored ST13P16 profile across patient tissues and cancer cell-line models. ST13P16 expression is associated with patient survival in 11 of 34 cancer types, with the highest sampling consensus in CHOL. Among the 18 cancer types available for tumor–normal comparison, ST13P16 is differentially expressed in 7, with the highest sampling consensus in BRCA. Additionally, ST13P16 RNA expression shows 7,304 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight CHOL, BRCA, and THYM as cancer lineages where ST13P16 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ST13P16 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ST13P16 survival associations across molecular data types. ST13P16 RNA expression shows survival associations in the most cancer types (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ST13P16 RNA expression–survival associations across cancer types. High ST13P16 expression shows unfavorable associations in CHOL, PAAD, READ, STAD and MESO, but favorable associations in LUAD. The CHOL Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify CHOL as the clearest survival context for ST13P16 RNA expression.
This table summarizes ST13P16 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for ST13P16. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ST13P16 shows lower tumor expression in LUSC, THCA and LUAD and higher tumor expression in BRCA, ESCA and PRAD. The BRCA box plot shows higher ST13P16 RNA expression in tumor versus normal tissue (log2 FC = +0.039, t-test p = .034).
This table shows molecular features associated with ST13P16 in patient tissues and cancer cell lines. In patient samples, ST13P16 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
